Role of hemodynamic forces in the ex vivo arterialization of human saphenous veins  by Berard, Xavier et al.
From
of
Su
La
U
The
da
tio
Fo
Ju
th
BERole of hemodynamic forces in the ex vivo
arterialization of human saphenous veins
Xavier Berard, MD, PhD,a Sébastien Déglise, MD,b Florian Alonso, PhD,b François Saucy, MD,b
Paolo Meda, MD,c Laurence Bordenave, MD, PhD,a Jean-Marc Corpataux, MD,b and
Jacques-Antoine Haeﬂiger, PhD,b Bordeaux, France; and Lausanne and Geneva, Switzerland
Background: Human saphenous vein grafts are one of the salvage bypass conduits when endovascular procedures are not
feasible or fail. Understanding the remodeling process that venous grafts undergo during exposure to arterial conditions
is crucial to improve their patency, which is often compromised by intimal hyperplasia. The precise role of hemodynamic
forces such as shear stress and arterial pressure in this remodeling is not fully characterized. The aim of this study was to
determine the involvement of arterial shear stress and pressure on vein wall remodeling and to unravel the underlying
molecular mechanisms.
Methods: An ex vivo vein support system was modiﬁed for chronic (up to 1 week), pulsatile perfusion of human saphenous
veins under controlled conditions that permitted the separate control of arterial shear stress and different arterial pressure
(7 mm Hg or 70 mm Hg).
Results: Veins perfused for 7 days under high pressure (70 mm Hg) underwent signiﬁcant development of a neointima
compared with veins exposed to low pressure (7 mmHg). These structural changes were associated with altered expression
of several molecular markers. Exposure to an arterial shear stress under low pressure increased the expression of matrix
metalloproteinase (MMP)-2 and MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 at the transcript, protein,
and activity levels. This increase was enhanced by high pressure, which also increased TIMP-2 protein expression despite
decreased levels of the cognate transcript. In contrast, the expression of plasminogen activator inhibitor-1 increased with
shear stress but was not modiﬁed by pressure. Levels of the venous marker Eph-B4 were decreased under arterial shear
stress, and levels of the arterial marker Ephrin-B2 were downregulated under high-pressure conditions.
Conclusions: This model is a valuable tool to identify the role of hemodynamic forces and to decipher the molecular mech-
anisms leading to failure of human saphenous vein grafts.Under ex vivo conditions, arterial perfusion is sufﬁcient to activate
the remodeling of human veins, a change that is associated with the loss of speciﬁc vein markers. Elevation of pressure
generates intimal hyperplasia, even though veins do not acquire arterial markers. (J Vasc Surg 2013;57:1371-82.)
Clinical Relevance: The pathological remodeling of the venous wall, which leads to stenosis and ultimately graft failure, is
the main limiting factor of human saphenous vein graft bypass. This remodeling is due to the hemodynamic adaptation of
the vein to the arterial environment and cannot be prevented by conventional therapy. To develop a more targeted
therapy, a better understanding of the molecular mechanisms involved in intimal hyperplasia is essential, which requires
the development of ex vivo models of chronic perfusion of human veins.The number of patients with peripheral arterial
occlusive disease is increasing worldwide in the aging pop-
ulation.1 Today, endovascular procedures are preferred to
bypass grafting as ﬁrst-line therapy for critical limb ischemia
because of lower morbidity and mortality rates. However,
when endovascular therapy fails or is not applicable
(eg, in the case of extensive occlusive lesions), bypass graft-
ing of autologous saphenous vein remains the rescue
therapy of choice.2 Failure of such a vein graft is mostly
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metalloproteinase,8 and inhibitor systems,9 are involved
in IH.10 These changes cause the stiffening of the vein
graft, limiting its ability to adapt to the arterial circulation.
However, the involved molecular mechanism has been only
marginally elucidated.11 Some grafts escape this deleterious
evolution because of adequate adaptation to the arterial
environment.3 Among the various hemodynamic forces
encountered in the arterial system, shear stress seems the
most prominent component,12 whereas the role of pressure
is less clear. Most previous studies monitored development
of IH under low shear stress conditions,13 eliminating the
involvement of arterial pressure.
We used an ex vivo vein support system (EVVSS) that
allowed us to study the wall remodeling of segments of
human saphenous veins exposed to various hemodynamic
conditions that characterize the arterial compartment.14,15
Using such a system, we previously reported that IH
increased with plasminogen activator inhibitor (PAI)-1
activity in veins exposed to arterial conditions.7 We now
provide evidence that arterial shear stress and pressure differ-
entially impinge on the mechanisms involved in this
arterialization.
METHODS
Human saphenous veins. We obtained 17 surplus
segments of nonvaricose human saphenous veins from 15
patients (eight men and seven women) with a median
age of 69 years (interquartile range, 51–80), who under-
went lower limb bypass surgery for critical limb ischemia.
A segment >3 cm of the greater saphenous vein was har-
vested and immediately stored at 4C in a RPMI-1640
medium supplemented with GlutaMAX and 30% fetal calf
serum (Gibco, Grand Island, NY). A segment of at least 2
cm length was perfused for 7 days (arterial shear stress),
and another segment (control) was either ﬁxed in formalin
(one half) or rapidly frozen in liquid nitrogen (the other
half). The ethical committee of the University of Lausanne
approved the experiments, which are in accordance with
the principles outlined in the Declaration of Helsinki for
use of human tissue.
Ex vivo perfusion system. The EVVSS7 consists of a
gearing pump (Reglo-Z; Ismatec, Glattbrugg, Switzerland)
that induces a pulsatile signal of 60 pulses/min and
constant amplitude generating an unidirectional ﬂow of
80 6 15 mL/min independently from the pressure applied
in the system.7,14,15 This cardioid signal was produced by
an arbitrary waveform generator controlled by a computer
(National Instruments PCI-6024 E Acquisition card;
National Instruments, Austin, Tex). The driving software
integrated constant acquisition and monitoring of pres-
sures, ﬂow velocity, pulse rate, and signal (Labview;
National Instruments). The vein segment was connected to
the perfusion pump by peroxide-treated silicone tubing
(internal diameter 3.2 mm; Ismatec) and maintained at
37 6 0.1C inside a perfusion chamber, which was placed
inside a cell culture incubator (Model 310; Forma Scientiﬁc
Inc, Marietta, Ohio). In all experiments, the culturemedium of both the chamber (250 mL) and the perfusate
(150 mL) was RPMI-1640, supplemented with Glutamax,
30% fetal calf serum (Gibco), 8% 70-kDa dextran (Sigma),
and 1% antibiotic-antimycotic solution (penicillin G,
10,000 units/mL; streptomycin sulfate, 10,000 mg/mL;
amphotericin B, 25 mg/mL; and gentamicin, 0.5 mg/mL).
The pH value was kept constant at 7.40 6 0.01 using
a CO2/pH algorithm based on the Henderson-Hasselbach
equation. Vein segments were perfused for 7 days,16 and
the culture media changed every 2 days. In this system, the
shear stress (SS) was given by SS ¼ 4 mQ/pr3, where m is
the viscosity (dyn$s/cm2); Q, the ﬂow rate (mL/s); and r,
the radius of the vein segment (cm). The medium viscosity
was 3.73 102 dyn$s/cm2, as measured in a Coulter
viscometer (Coulter Electronics, High Wycombe, UK).
Given that the radius of the perfused veins was not altered
during the perfusion, the shear stress could be considered
essentially constant, whatever the pressure applied to the
system. This stress was set at a value of 9 to 15 dyn/cm2,
which corresponds to the value expected in the arterial
system. Under these conditions, the system allows for an
evaluation of the effects of different imposed pressures.
Mean pressure (MP) was given by MP ¼ (systolic
pressure þ 2  diastolic pressure)/3. In a ﬁrst series of
experiments (eight vein segments), we tested the effects of
a systolic/diastolic pressure of 8 6 1/6 6 1 mm Hg
(mean pressure ¼ 7 mm Hg) obtained by the perfusion
pump that produced the arterial ﬂow. In a second series of
experiments (nine vein segments), under the same arterial
ﬂow, the level of systolic/diastolic pressure was increased
to 90 6 5/65 6 5 mm Hg (mean pressure ¼ 70 mm
Hg), using a second pump, to be representative of a normal
arterial compartment. This mean pressure, reproducing the
normal mean arterial pressure in humans, could be main-
tained throughout the 7 days of in vitro perfusion. After
the 7-day perfusion, the veins were removed from the
system, and the distal and proximal 5-mm segments, which
served to attach the vessel to the perfusion equipment, were
discarded. A central, 5-mm-thick ring was sampled for
morphometry. The two remaining vein fragments were
reduced into powder for reverse transcriptase polymerase
chain reaction (RT-PCR) and Western blot analysis.
Morphometry. A 5-mm-thick ring was harvested
before (control) and after a 7-day-long perfusion (arterial
shear stress) from the central portion of each vein segment.
Hematoxylin-eosin and Van Gieson elastin stains were used
for histologic and morphometric analysis. For morphom-
etry, digital pictures were taken and measurements per-
formed with software KS 400 (Carl Zeiss, Oberkochen,
Germany). For each sample, 24 measurements of intima
and media thickness were processed at a magniﬁcation
of 20 and 1.25.
Quantitative RT-PCR. Quantitative RT-PCR was
performed on RNA of human saphenous vein treated for
30 minutes in the presence of DNase I (DNA-free kit;
Ambion, Cambridge, UK). For reverse transcription, 1 mg
of RNA was used (Promega, Madison, Wisc). Human
matrix metalloproteinase (MMP)-2 and MMP-9, tissue
Table. Human primers for quantitative reverse transcriptase polymerase chain reaction (RT-PCR)
Gene Sense primer (5 0-3 0) Antisense primer (5 0-3 0)
PAI-1 GGCTGGTGCTGGTGAATG ATCGGGCGTGGTGAACTC
MMP-2 CAGAGCCACCCCTAAAGAGA TGTGAAAGGAGAAGAGCCTGA
MMP-9 GCCACTTCCCCTTCATCTTC GTCGTCGGTGTCGTAGTTGG
TIMP-1 TGACATCCGGTTCGTCTACA TGCAGTTTTCCAGCAATGAG
TIMP-2 AAGCGGTCAGTGAGAAGGAA TCTCAGGCCCTTTGAACATC
Ephrin-B2 CTTTGGAGGGCCTGGATAAC CTGTTGCCGTCTGTGCTAGA
Eph-B4 CGCAGACCAAAGAGAGTGTG GGGACTACAAACCCCAATGA
GAPDH AACTTTGGTATCGTGGAAGG CAGTAGAGGCAGGGATGATGT
GADPH, Glyceraldehyde 3-phosphate dehydrogenase; MMP-2/-9, matrix metalloproteinase-2/-9; PAI-1, plasminogen activator inhibitor-1; TIMP-1/-2,
tissue inhibitor of metalloproteinase-1/-2.
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plasminogen activator inhibitor PAI-1, and Ephrin-B2
and Eph-B4 mRNA levels were determined by quantita-
tive RT-PCR, using the Fast SYBR Green Master Mix
(Applied Biosystems, Carlsbad, Calif) in a ViiA7 Instru-
ment (Applied Biosystems). The primers used to amplify
speciﬁc cDNAs from human saphenous veins are given in
the Table and were designed using the free online software
Primer3 (http://frodo.wi.mit.edu/primer3/). All experi-
ments included negative controls (ampliﬁcation of distilled
water or RNA samples that had not been subjected to
reverse transcription).17,18
Western blots. Segments of saphenous veins were
reduced to powder and homogenized in lysis buffer as
published previously.17,18 Samples of total vessel extracts
(25 mg) were resolved by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) (10%) and
transferred to a polyvinylidene diﬂuoride membrane
(Immobilon-P; Millipore, Billerica, Mass). The membrane
was incubated with a primary antibody overnight at 4C,
washed in TBS-T, and incubated for 1 hour with a horse-
radish peroxidase-linked antibody against mouse (Southern
Biotech, Birmingham, Ala), rabbit (Thermo Fisher Scien-
tiﬁc, Waltham, Mass), or goat IgGs (Sigma-Aldrich,
St. Louis, Mo), whichever was deemed adequate. Immu-
nostaining was revealed by chemoluminescence, using
ECL-plus kit (GE Healthcare, Uppsala, Sweden). The
following primary antibodies were used: mouse monoclonal
against MMP-2 (Chemicon, Temecula, Calif), mouse
monoclonal against MMP-9 (Chemicon—this antibody
recognizes both the pro- and the active forms of MMP-9),
mouse monoclonal against TIMP-2 (R&D Systems,
Minneapolis, Minn), rabbit polyclonal against PAI-1
(Novus Biologicals, Littleton, Colo), and goat polyclonal
against TIMP-1 (R & D Systems). The former four anti-
bodies were used at a dilution 1:1000. The latter three were
used at a dilution 1:500. To check the total protein levels,
membranes were probed with polyclonal antibodies against
alpha actin (BD Transduction, Lexington, Ky).
Immunocytochemistry. The above-mentionedprimary
antibodies were also used at a dilution of 1:100. Binding
sites of the different antibodies were visualized using an
avidin-biotinylated horseradish-peroxidase complex (Vec-
tastain Elite ABC Kit; Vector Laboratories, Burlingame,Calif). After rinsing in phosphate-buffered saline, the
product of the peroxidase reaction was visualized using
0.1% 3,3-diaminobenzidine tetrahydrochloride dehydrate,
dissolved in phosphate-buffered saline containing 0.3%
H2O2. Antibody binding was revealed using the avidin-
biotin peroxidase technique. When needed, sections were
counterstained with hemalum to visualize cell nuclei.
Zymography. For zymography, 20-mg total protein
extracts of veins were incubated in Laemmli buffer devoid
of mercaptoethanol and resolved on 10% SDS-PAGE con-
taining 0.1% gelatin. The gels were incubated at 37C over-
night in the developing buffer (50 mM Tris, pH 7.4, 0.2 M
NaCl, 5 mM CaCl2, 0.1% triton X-100) to allow for gelatin
degradation. The gels were stained with 0.25% Coomassie
blue (50% methanol, 10% acetic acid) and destained (50%
methanol, 10% acetic acid). Recombinant human MMP-2
(0.5 ng; Calbiochem, Darmstasdt, Germany) and MMP-9
(0.25 ng; Calbiochem) were used as positive controls. The
gels were scanned and intensities were determined with the
National Institutes of Health 1.62 image analyzer software.
Statistical analysis. All experiments were quantitatively
analyzed, and results were shown asmean6 standard error of
the mean. Student t-test and two-way analysis of variance
were performed to compare themean values between groups,
using the post hoc Bonferroni test, as provided by the
Statistical Package for the Social Sciences (SPSS 17.0;
Chicago, Ill). Statistical signiﬁcance was set at P < .05.RESULTS
Intimal hyperplasia is initiated by high pressure. In
preliminary experiments (n ¼ 3) dedicated exclusively to
morphometry analysis (at both low-pressure and high-
pressure conditions), no regional variations in the pres-
ence of hyperplasia were observed all along the human
saphenous vein segment (data not shown). In another
series of preliminary experiments (four veins), we observed
no IH after 3 days of perfusion. Morphometric analysis
showed that compared with the segments of freshly iso-
lated veins (control), the segments of the same veins that
were exposed for 7 days to arterial shear stress and high
pressure underwent signiﬁcant IH, despite stable thickness
of the media layer (Fig 1). As a result, the intima-to-media
ratio was increased (Fig 1). In contrast, no IH was
Fig 1. Intimal hyperplasia develops within 7 days of ex vivo pulsatile perfusion. Upper panel, Representative histo-
logical sections show the normal intima thickness (arrow) in nonperfused veins (control) and veins perfused at low
pressure (arterial shear stress [SS] 7 mmHg). In contrast, intimal hyperplasia (arrow) is evident in veins perfused at high
pressure (arterial SS 70 mm Hg). L, Lumen; M, media. Bar represents 50 mm. Lower panels, Measurements of intima
thickness show that intimal hyperplasia was induced by perfusion at high pressure (70 mm Hg), despite unchanged
thickness of the media layer. Data represent mean 6 standard error of the mean of two series of eight and nine
experiments. *P < .05 and ***P < .001 vs the nonperfused segments (controls) of the same veins.
JOURNAL OF VASCULAR SURGERY
1374 Berard et al May 2013observed in veins exposed to the same shear stress but low-
pressure conditions (Fig 1).
Staining with hematoxylin-eosin showed the proper
outline of endothelial cell nuclei along the lumen of all
vessels and the abnormal presence of SMC nuclei in the
regions of IH (Fig 2). Immunostaining using antibodies
against von Willebrand factor and alpha-smooth muscle
cells further conﬁrmed the lining of endothelial cells atthe luminal surface of all veins and the SMCs in the media,
whatever the experimental protocol (Fig 2). Numerous
SMCs further colonized the intima at regions of IH
(Fig 2). Immunolabeling using antibodies against KI-67,
a marker speciﬁcally expressed by proliferating cells,
revealed the presence of proliferating SMCs in the regions
of IH (Fig 2). Each vessel segment was assessed for viability
of both intima and media layers before and after perfusion
Fig 2. Human saphenous veins after 7 days of ex vivo perfusion show persistence of endothelial cells and altered
distribution of smooth muscle cells (SMCs). Upper row, Hematoxylin-eosin staining (HE) reveals the lining of the
lumen by nuclei of endothelial cells and the nuclei of SMCs in the media layer. Nuclei of the latter cells were also
observed within the intimal hyperplasia regions (right panel). Middle rows, Immunolabeling using antibodies against
von Willebrand factor (vWf) or alpha-smooth muscle actin (SMA) demonstrate the presence of endothelial cells at the
luminal surface of all veins and of SMCs in the media of all vessels. SMCs were also detected in the intimal hyperplasia
regions (right panels). Lower row, Immunolabeling using antibodies against KI-67 (dark blue) revealed the presence of
proliferating SMCs mainly in the intimal hyperplasia regions. L, Lumen; M, media. Bars represent 100 mm in ﬁgures
and 400 mm in the insets.
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Fig 3. The expression of matrix metalloproteinase (MMP)-2 and MMP-9 is increased by arterial shear stress
(SS). A, MMP-2 transcripts are upregulated by arterial shear stress, and this upregulation is increased by high
pressure (70 mm Hg). B, Western blots showed increased levels of both MMP-2 and MMP-9 after perfusion,
under both low and high hemodynamic pressure. C and D, Both pro-MMP-2 and MMP-2 protein were
signiﬁcantly increased by perfusion and high pressure. E and F, MMP-9 transcript and protein levels were also
upregulated by perfusion. However, the MMP-9 protein did not appear to be further induced by high pres-
sure. Data represent mean 6 standard error of the mean of two series of eight and nine experiments. GADPH,
Glyceraldehyde 3-phosphate dehydrogenase. *P < .05; **P < .01; ***P < .001 vs nonperfused veins and veins
exposed to low pressure.
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incubation in the presence of vasoactive drugs as previously
described.7,14
Expression of MMP-2 and MMP-9 is increased by
perfusion. In the presence of low pressure, the expression
of MMP-2 and MMP-9 increased at both transcript and
protein levels, together with the activity of these metal-
loproteinases (Fig 3). Both MMP-2 and MMP-9 tran-
scripts increased by the perfusion and further enhanced in
the presence of high pressure (Figs 3 and 4). At the protein
level, both pro-MMP-2 and MMP-2 forms increased in
parallel with the transcript in veins perfused at low pressure
(Fig 3). However, although the levels of the MMP-2protein were increased further under high-pressure condi-
tions, MMP-9 levels were not (Fig 3). Immunostaining
further demonstrated that the expression of the two metal-
loproteinases was mostly increased in the media layer (Fig 4).
Quantitative evaluation of the zymographic gels (Fig 4)
showed that perfusion increased the lytic effect of MMP-2,
but not pro-MMP-2, in the presence of both low and high
pressure (Fig 4). MMP-9 was also upregulated after per-
fusion, whatever the hemodynamic pressure (Fig 4).
Markers TIMP-1, TIMP-2, PAI-1, Ephrin-B2, and
Eph-B4 are differentially modulated by the hemody-
namic pressure. At both transcript and protein level, the
expression of TIMP-1 was signiﬁcantly enhanced by
Fig 4. The lytic activity of matrix metalloproteinase (MMP)-2 and MMP-9 is increased by arterial shear stress (SS) and
blood pressure. A, Zymographic analysis distinguished the gelatin lysis induced by pro-MMP-2, MMP-2, and MMP-9.
B-D,Quantitative analysis showed that the activities of these enzymes increased in veins exposed to arterial shear stress.
However, only MMP-2 and MMP-9 were further enhanced by high pressure. Data represent mean 6 standard error of
the mean of two series of eight and nine experiments. *P < .05; **P < .01; ***P < .001 vs control veins or veins
submitted to low pressure. E, Immunostaining showed that both MMP-2 (top row) and MMP-9 (bottom row) increased
mostly within the media layer of the perfused veins. L, Lumen; M, media. Bars represent 100 mm.
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pressure (Fig 5). In contrast, the expression of the TIMP-2
transcript was downregulated after the 7-day-longperfusion, whatever the hemodynamic pressure (Fig 5).
The levels of the cognate protein were not altered under the
low-pressure regimen but were signiﬁcantly increased after
Fig 5. The inhibitors of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 are differentially affected by
arterial shear stress (SS) and pressure. A and B, Veins exposed to arterial shear stress featured increased expression of
TIMP-1 mRNA but decreased expression of the TIMP-2 transcripts. C, Consistent with the transcript change, Western
blots showed upregulation of the TIMP-1 protein in the presence of both low and high pressure.D, In marked contrast
to the mRNA changes, the levels of the TIMP-2 protein were markedly increased only in the presence of high pressure.
Data represent mean 6 standard error of the mean of two series of eight and nine experiments. *P < .05; **P < .01,
***P < .001 vs control veins. E, Immunostaining conﬁrmed that the abundance of TIMP-1-positive and TIMP-2-
positive smooth muscle cells increased under arterial hemodynamic conditions. GADPH, Glyceraldehyde 3-phos-
phate dehydrogenase; L, lumen;M, media; PAI, plasminogen activator inhibitor. Insets show the boxed areas at higher
magniﬁcation. Bars represents 100 mm in ﬁgures and 400 mm in the insets.
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Fig 6. The levels of plasminogen activator inhibitor (PAI)-1 increase in human saphenous vein exposed to arterial
shear stress (SS). A, PAI-1 transcripts were increased in human saphenous veins submitted to arterial shear stress. B and
C, Western blot analysis and immunocytochemistry showed that PAI-1 mostly increased in the media layer of the
arterializing veins. GADPH, Glyceraldehyde 3-phosphate dehydrogenase; L, lumen; M, media. Bar represents 50 mm.
Data represent mean6 standard error of the mean of two series of eight and nine experiments. **P < .01; ***P < .001
vs control veins.
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further demonstrated an increase in TIMP-1 and TIMP-2
expression in the SMCs of the media (Fig 5).
The expression of PAI-1 was elevated with the applica-
tion of ﬂow, without additional effect of high pressure
(Fig 6). Exposure to perfusion was sufﬁcient to downregu-
late Ephrin-B2 and Eph-B4 transcripts, whichever the
pressure (Fig 7). The cognate Eph-B4 protein was
decreased in all perfused veins (Fig 7). In contrast, the
levels of Ephrin-B2 were signiﬁcantly decreased only under
high-pressure conditions (Fig 7).DISCUSSION
Despite technological advances in endovascular ap-
proaches, bypass graft using saphenous veins still offers
valuable clinical results at both midterm and long term19
and retains a place of choice for vascular surgeons.
However, graft failure remains the main limiting factor
during the arterialization of the grafted veins, notablybecause of the development of aberrant IH. In this
context, shear stress plays a pivotal role, especially in the
regulation of vein caliber.20
The aim of this study was to evaluate the effect of arterial
pressure in the phenomenon of arterial remodeling encoun-
tered by a vein placed in arterial conditions because most of
the models reproducing IH in human vessels so far have
been developed under conditions of low shear stress.10,11,15
Thesemodels partially reproduce the conditions encountered
in zones of blood turbulence, such as anastomoses or valves,
where the shear stress is altered, and the risk of IH and focal
stenosis is great. The EVVSS model we tested cannot repro-
duce these local hemodynamic conditions. However, it
speciﬁcally allows testing of the effect of arterial pressure in
the presence of high shear stress (ie, the conditions that
prevail in the arterial compartment). Using this model, we
showed that under rigorously constant conditions of
medium, ﬂow rate, and shear stress, IH develops within 1
week when the mean hemodynamic pressure was that
observed in the arterial but not the venous compartments
Fig 7. The expression of Ephrin-B2 and Eph-B4 decreases in the presence of high pressure. A and B, The transcription
of Ephrin-B2 and Eph-B4 decreased in veins submitted to arterial shear stress (SS). C and D, The levels of the cognate
proteins were also reduced under these conditions. In vessels exposed to low pressure, only Eph-B4 was found
signiﬁcantly reduced. Data represent mean 6 standard error of the mean of two series of eight and nine experiments.
GADPH, Glyceraldehyde 3-phosphate dehydrogenase. **P < .01; ***P < .001 vs control veins.
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the conditions a vein faces when grafted on an arterial bed,
differ from those provided by previously published models,
which provided different interpretations about the role of
hemodynamic pressure21-24 on the vessel wall. Dobrin
et al21 explored vascular remodeling in venous graft inter-
posed in the femoral position in dogs after 3 months and
found an increase in medial thickness with no inﬂuence on
intimal thickness. Our ex vivo system also allows for compen-
sation for the possible inﬂuence that different anatomical
locations may have on the arterialization of grafted veins,
providing a unique platform to explore the different factors
that may contribute to modify the grafted vessels.3,25
Remodeling requires the integrated effects of the
ﬁbrinolytic system, MMPs, and their inhibitors. We have
shown that elevation of PAI-126 is induced by the arterial
shear stress and, in contrast to IH, is not markedly inﬂuenced
by the hemodynamic pressure. If PAI-1 promotes IH in
response to vascular injury,27-31 this factor is unlikely to be
the primary event triggering the pressure-dependent IH
remodeling of the vein wall under arterializing conditions.
During this remodeling, degradation of the extracellularmatrix by enzymes of the MMP family could conceivably
facilitate the migration of SMCs from themedia to the intima
layer.32 Consistent with this scenario, MMP-2 expression has
been reported to increase in saphenous veins exposed to
arterializing conditions analogous to the conditions we
have tested.33We document that the arterial shear stress asso-
ciated with elevated ﬂow rate of perfusion is sufﬁcient to
increase the expression of both MMP-2 and MMP-9, via
an upregulation of the transcription of the cognate genes.
We further show that the high pressure, which plays a key
role in initiating IH, further increases the production of
bothMMPs, resulting in a marked enhancement of their lytic
activity with a more pronounced effect on the MMP-2 active
form. This observation is consistent with the report that
MMP-2 is the predominant metalloproteinase involved in
the early phase of development of IH.34 Our study conﬁrms
in human veins that compared with MMP-2, MMP-9 seems
likely to have a lesser effect, given that its expression was not
altered by high pressure. However, this difference could be
explained by a difference in the temporal proﬁle of MMP
expression. TIMPs counterbalance the role played by
MMPs in the degradation of many extracellular matrices.35
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grafted in various arterial compartments36 but to increase
with MMP-2 and MMP-9 in an ex vivo system of high
ﬂow.36 We now document that arterial shear stress is sufﬁ-
cient to increase the expression of TIMP-1 and that
a concomitant increase in hydrodynamic pressure is further
required to activate the expression of TIMP-2. After 7 days
of perfusion, the levels of TIMP-2 RNA were reduced,
whereas the cognate protein was increased. This apparent
discrepancy may be accounted for by a different temporal
regulation proﬁle of TIMP-2 transcript and protein, consis-
tent with the ﬁndings in other models that tested experi-
mental protocols different from the one we investigated.34,37
These ﬁndings suggest that TIMP-2 plays a relevant
role, together with MMP-2 and MMP-9, in initiating or
sustaining IH, or both. The relationship between the
TIMP-2 changes and IH is complex, as exempliﬁed by
the ﬁnding that IH is attenuated by exposure of vein grafts
to the inhibitor.38
A previous study indicated that adaptation of vein
grafts to an arterial environment is also associated with
loss of Eph-B4, a venous marker, but not with the gain
of Ephrin-B2, an arterial marker.39 Our ex vivo experi-
ments extend these observations by showing that the
combination of pulsatile ﬂow and high pressure was insuf-
ﬁcient to induce an extensive remodeling of all layers of the
grafted vessel to replace an arterial segment fully.40 We
have also shown that the reduction of Eph-B4 expression
that corresponds to the loss of venous identity is associated
with the presence of a condition of arterial perfusion stress
and that this phenomenon is independent of the hemody-
namic pressure. The IH is not associated with a further
decrease in Eph-B4 levels under conditions of high shear
stress. These ﬁndings suggest the possibility that a pharma-
cological approach may be able to foster the extensive wall
remodeling that would be required for veins to replace
arterial segments fully.11
It is recognized that the EVVSS model we used also
features limitations. First, the paucity of the human mate-
rial prevented us from perfusing vein segments under
conditions—notably low shear stress—mimicking those
of the venous compartment. Under such conditions, it is
possible that vein segments may have developed alter-
ations that were not detected in the freshly sampled, non-
perfused controls we used. Second, based on a set of
preliminary experiments, we tested the venous arterializa-
tion at a single time point (7 days of perfusion). This
single time point prevents us from determining the precise
time course of the alterations we document here, which
our data suggest should start after 3 to 7 days of contin-
uous perfusion. Third, the ex vivo conditions of the model
prevent us from determining the concurrent participation
of extravascular cell types, notably bone marrow–derived
cells.6 Because we could not isolate sufﬁcient amounts of
endothelial cells and test venous segments devoid of the
intima layer, our data do not deﬁnitively establish whether
SMCs and/or endothelial cells are mainly responsible
for the alterations of the venous wall during IH. Apredominant increase of the former cell type is favored
by the increased numbers of SMCs in the regions of IH
and their altered expression in metalloproteases and their
inhibitors.
CONCLUSIONS
Our data provide evidence that arterial shear stress and
hydrodynamic pressure have distinct effects on the remod-
eling of the wall of human veins during the ﬁrst week of
arterialization, and we report the crucial role of high
pressure on the development of IH. The data have begun
elucidating some of the molecular participants of this
complex process, whose expression is differentially regu-
lated by various hemodynamic parameters. The ex vivo
system we have developed is suitable to explore innovative,
molecular-targeted strategies for the prevention of IH.
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